80B61352-E9FC-4B3E-BAA8-ECBFD2A6E9B3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.38107752956636
- age_years
- 69
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.449
- INTERFERON_GAMMA_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.397
- BILE_ACID_METABOLISM+0.345
- IL2_STAT5_SIGNALING+0.278
- APOPTOSIS+0.277
- INFLAMMATORY_RESPONSE+0.254
- COMPLEMENT+0.245
- ADIPOGENESIS+0.227
- DNA_REPAIR+0.226
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.414
- PANCREAS_BETA_CELLS-0.335
- KRAS_SIGNALING_DN-0.297
- PI3K_AKT_MTOR_SIGNALING-0.122
- APICAL_JUNCTION-0.118
- ANGIOGENESIS-0.111
- MYOGENESIS-0.109
- UV_RESPONSE_DN-0.104
- SPERMATOGENESIS-0.089
- OXIDATIVE_PHOSPHORYLATION-0.041
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1415337 | GTEX | — | 0.850 |
| 2 | 433EA1F9-8F58-45FF-A330-50049827D332 | — | — | 0.848 |
| 3 | 1C62E679-3A4E-4D10-8BFB-5BFBF2A3B4B6 | — | — | 0.827 |
| 4 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.811 |
| 5 | 575F780D-9288-44CC-A0EA-E28EAD80213B | — | — | 0.804 |
| 6 | C1CCE12B-8892-49AB-8DF2-E5E280DEAE32 | — | — | 0.796 |
| 7 | 5C40F9B6-4A54-4861-9DE5-8852BF4B13E7 | — | — | 0.790 |
| 8 | MNG1002 | — | — | 0.787 |
| 9 | SRR934811 | — | — | 0.785 |
| 10 | 722B7A0F-BF34-4368-8CFF-944FCBC7DAC4 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.449 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.397 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.345 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.278 | Idelalisib | — uncovered |
| APOPTOSIS | 0.277 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.254 | Idelalisib | — uncovered |
| COMPLEMENT | 0.245 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.227 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.226 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.196 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.194 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.191 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.191 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.189 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.172 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.161 | Idelalisib | — uncovered |
| PEROXISOME | 0.155 | Idelalisib | — uncovered |
| COAGULATION | 0.149 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.148 | Idelalisib | — uncovered |